伊伐布雷定治疗扩心病心力衰竭的疗效观察  

Efficacy of Ivabradine in the Patients With Chronic Heart Failure Resulting From Dilated Cardiomyopathy

作　　者：于晓斌[1] 张豪英[2] 邢冬杰[2] YU Xiaobin;ZHANG Haoying;XING Dongjie(Department of Organization and Personnel,Shandong College of Traditional Chinese Medicine,Yantai Shandong 264199,China;Department of Western Medicine Teaching,Shandong College of Traditional Chinese Medicine,Yantai Shandong 264199,China)

机构地区：[1]山东中医药高等专科学校组织人事处,山东烟台264199 [2]山东中医药高等专科学校西医教学部,山东烟台264199

出　　处：《中国卫生标准管理》2019年第22期68-71,共4页China Health Standard Management

摘　　要：目的观察伊伐布雷定治疗扩心病心力衰竭的疗效。方法前瞻性地纳入2015年1月-2018年12月期间符合条件的心力衰竭(heartfailure,HF)患者66例。收集所有研究对象的一般临床资料。应用随机数字表将研究对象随机分为对照组33例和试验组33例。对照组给予常规的心衰药物治疗,试验组在此基础上加用伊伐布雷定。治疗3个月后,复查所有参与者的心率、血压、左室射血分数(left ventricular ejection fraction,LVEF)、B型利钠肽(B-type natriuretic peptide,BNP)以及6 min步行实验。结果治疗3个月后,试验组有23例(69.7%)的伊伐布雷定用量达到目标靶剂量。试验组心率显著低于对照组,而心率达标率显著高于对照组。试验组的纽约心脏病学会(New York Heart Association,NYHA)分级、BNP水平均显著低于对照组,而6 min步行距离、LVEF均显著高于对照组。结论伊伐布雷定能够有效地控制扩心病心衰患者的心率,改善心衰治疗效果。Objective To explore the efficacy of ivabradine in the patients of with chronic heart failure resulting from dilated cardiomyopathy. Methods 66 eligible patients with HF were prospectively included between January 2015 and December 2018 General clinical data were collected from all subjects. The subjects were randomly divided into the control group of 33 cases and the test group of 33 cases using a random number table. The control group was given conventional medication for heart failure, and the test group was given ivabradine on the basis of the control group. After 3 months of treatment, all participants were reviewed for heart rate, blood pressure, LVEF, BNP, and 6-minute walking distance. Results After 3 months of treatment, ivabradine used in 23 cases(69.7%) of the test group reached to the target dose. The heart rate of the test group was significantly lower than that of the control group, and the heart rate compliance rate was significantly higher than that of the control group. The NYHA classification and BNP level of the test group were significantly lower than those of the control group, and the walking distance of 6 minutes and LVEF were significantly higher than those of the control group. Conclusion Ivabradine can effectively control the heart rate of patients with heart failure and improve the treatment of heart failure, which is worthy of further application in clinical practice.

关 键 词：伊伐布雷定 心力衰竭 扩张型心肌病 心率 左室射血分数 B型利钠肽 

分 类 号：R541[医药卫生—心血管疾病]